Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06825793
NA

Semaglutide's Weight Loss Effects in Obesity

Sponsor: Beijing Chao Yang Hospital

View on ClinicalTrials.gov

Summary

This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.

Official title: Clinical Assessment of Semaglutide-Induced Weight Reduction in Obese Populations

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

56

Start Date

2025-02-20

Completion Date

2027-12-31

Last Updated

2025-02-13

Healthy Volunteers

No

Conditions

Interventions

DRUG

Semaglutide Subcutaneous Injection

All subjects received subcutaneous injections of semaglutide over a 28-week treatment period, which included an initial 16-week dose-escalation phase. The escalation protocol began with a starting dose of 0.25 mg administered once weekly. Every 4 weeks, the dose was gradually increased in a stepwise manner to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each administered once weekly.